Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It ...

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

When lenacapavir test results were presented at a World AIDS Conference in July 2024, experts were thrilled: Lenacapavir was hailed as a long-awaited breakthrough in the fight against HIV/AIDS. "I ...

While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...

HIV effort. More people than ever are receiving antiretroviral treatment and have viral suppression. Deaths from AIDS are at ...

Biannual vaccinations with the drug lenacapavir offers effective protection against HIV infection, according to phase-3 study ...

The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 ...

A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published ...

"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...

Recent results from a recent clinical trial indicate that a twice-yearly injection of Lenacapavir offers an overall 96% reduced risk of acquiring HIV. This makes Lenacapavir significantly more ...